Should rosuvastatin be withdrawn from the market?

被引:7
作者
Cohen, JS [1 ]
机构
[1] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA
[2] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA
关键词
D O I
10.1016/S0140-6736(04)17304-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1579 / 1579
页数:1
相关论文
共 5 条
[1]  
Blenkinsopp J, 2003, LANCET, V362, P1854, DOI 10.1016/S0140-6736(03)14909-4
[2]   Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines [J].
Grundy, SM ;
Cleeman, JI ;
Merz, CNB ;
Brewer, HB ;
Clark, LT ;
Hunninghake, DB ;
Pasternak, RC ;
Smith, SC ;
Stone, NJ .
CIRCULATION, 2004, 110 (02) :227-239
[3]   Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia [J].
Olsson, AG ;
Pears, J ;
McKellar, J ;
Mizan, J ;
Raza, A .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (05) :504-508
[4]   Safety and efficacy of rosuvastatin [J].
Olsson, GO .
LANCET, 2004, 364 (9429) :135-135
[5]  
WOLFE SM, PETITION FDA REMOVE